4-HO-MET

The exact identity is 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET; metocin), not 4-AcO-MET. The current federal Criminal Code Regulations expressly list 4-AcO-MET, and the Criminal Code analogue provision specifies replacement of acyloxy with hydroxy as one listed structural-modification route; under the statutory analogue provision, 4-HO-MET is covered as a Commonwealth controlled drug. The Poisons Standard separately lists psilocin and other named tryptamines but no exact 4-HO-MET name; its derivative guidance requires a balanced case-specific assessment, and 4-HO-MET is not expressly named as a Schedule 9 entry. The current Customs compilation likewise does not expressly list 4-HO-MET in Schedule 4; regulation 5’s import prohibition applies to a Customs-defined drug, and 4-HO-MET has no independent exact-name Customs classification. Queensland independently and expressly lists 4-HO-MET in Schedule 2 and criminalizes unlawful possession. Australian State and Territory implementation can differ, and federal analogue coverage depends on establishing the sample’s identity and applying the statutory elements; non-Queensland states may use different schedule wording.

4-HO-MET (4-hydroxy-N-methyl-N-ethyltryptamine; metocin) is a substituted tryptamine and is covered by the current NPSV generic Tryptamin-Verbindungen definition. It is not individually named in the current Suchtgiftverordnung schedules. The NPSG regime principally criminalizes benefit-intended manufacture/import/export/transfer/supply with intended psychoactive use and allows seizure/forfeiture; the statutory medicines and Suchtmittelgesetz exclusions and lawful-use exceptions remain applicable.

4-HO-MET (metocin; 4-hydroxy-N-ethyl-N-methyltryptamine) is covered by Belgium's generic Annex IVA item 5 tryptamine structure: the terminal N-ethyl and N-methyl groups satisfy R1/R2, the indole-4-OH satisfies R3, and the indole N-H satisfies R4. The decree's authorization regime therefore makes import, export, transport, manufacture, possession, sale, supply, delivery and acquisition prohibited absent the applicable prior authorization, which is personal and limited to scientific or medical purposes. AFMPS warns that its consolidated PDF and indicative list are non-official/non-limitative; the Belgian Official Journal annexes and amendments control. The June 2026 Annex IVA amendment concerns only the synthetic-cannabinoid table and does not alter item 5.

4-HO-MET is expressly named as 4-hydroxy-N-methyl-N-ethyltryptamine (Metocin) in Bulgaria's Appendix No. 1 List I. List I is the high-risk category prohibited for human and veterinary application. Article 30 of the Narcotic Substances and Precursors Control Act prohibits ordinary handling and possession of List I plants, substances and preparations; Article 31 preserves only limited quantities provided under the Act for medical, scientific, laboratory-research or educational purposes. State Gazette amendment No. 73/2026 leaves the named 4-HO-MET row unchanged.

4-HO-MET (metocin; 4-hydroxy-N-ethyl-N-methyltryptamine) matches Hungary's current generic Annex 3 tryptamine definition: its tryptamine nitrogen bears ethyl and methyl groups, and its indole ring bears hydroxy at position 4. The current administrative regime requires an activity permit for listed operations and allows use only for research or industrial purposes (subject to the cited statutory exception). 4-HO-MET falls within generic NPS structural coverage but is not individually named in Annex 1 or Annex 2 as a narcotic or psychotropic substance.

Japan's current primary MHLW sources classify 4-HO-MET as prohibited. 4-HO-MET is expressly listed as a designated drug, including its salts, in both the current MHLW list and consolidated designated-drug ordinance. Under PMD Act Article 76-4, ordinary recreational manufacture, import, sale, transfer, possession, purchase, receipt and use are prohibited outside legally defined medical or other permitted uses. The current MHLW narcotic designation decree/list does not contain an exact 4-HO-MET entry. The explicit designated-drug classification applies rather than a named-narcotic classification.

4-HO-MET falls within Lithuania's current generic tryptamine-derivative entry in List I but is not listed by exact name. Its 4-hydroxy indol-3-ylethanamine core and N-ethyl/N-methyl amino substitution fall within item 137. The current Control Act makes the same control regime automatic for derivatives in a listed group and prohibits List I lawful circulation except narrow registered-medicine, research, official-function and accredited-laboratory exceptions.

4-HO-MET is expressly named in Poland's current psychotropic-substance schedule as Group I-P item 47, not merely covered as an unlisted new psychoactive substance. Group I-P substances may be used only for research under Article 33(2), while possession, unlawful manufacture and unlawful market placement are criminalized under Articles 53, 56 and 62. The schedule's concluding clause includes possible salts and stereoisomers unless expressly excluded. Article 62a is a discretionary procedural discontinuance rule for insignificant own-use amounts, not a legalization or possession exemption.

4-HO-MET is expressly named in Sweden's current Annex 1 narcotics schedule under Hallucinogener, and section 2 of the Narcotics Control Ordinance makes Annex 1 substances narcotics under the Narcotic Drugs Penal Law. The Narcotic Drugs Control Act restricts possession and other ordinary handling to enumerated authorized purposes, while the Penal Law criminalizes unauthorized possession, use, and other handling. It is prohibited, subject to the statutory permit and purpose-based exceptions in the cited provisions.

4-HO-MET is controlled in the United Kingdom under the generic tryptamine provision; group or analogue treatment remains dependent on the cited statutory scope.

4-HO-MET is expressly covered by Finland's current consumer-market prohibition schedule. The consumer-market prohibition is distinct from the Narcotics Act's narcotic-schedule status and has statutory research and industrial exceptions; it does not mean that every possible handling is prohibited.

4-HO-MET is controlled in Germany under the NpSG tryptamine-group provision; group or analogue treatment remains dependent on the cited statutory scope.

Portugal expressly lists 4-HO-MET (4-hidroxi-N-metil-N-etiltriptamina) as a new psychoactive substance. The Decreto-Lei 54/2013 framework prohibits ordinary production, import, export, advertising, distribution, sale, possession and making available, subject to duly authorized industrial or pharmaceutical purposes. Article 10(2) separately applies the Law 30/2000 personal-use regime with necessary adaptations to detention for mere own consumption; Lei 55/2023 clarifies the ten-day amount as an indicium and the administrative/referral consequences when exclusive own use is proved. Because 4-HO-MET is an expressly listed NPS under a distinct administrative prohibition regime rather than a named Decreto-Lei 15/93 narcotics-table entry, the regime does not treat every personal-use circumstance as an independently criminal possession offense.

4-HO-MET is expressly listed in Slovakia's current risk-substances list as item 14, under the Slovak term riziková látka. It is not individually named in the current Annex 1 narcotic/psychotropic schedule, which separately lists compounds such as DET, DMT, Etryptamín and 5-MeO-DALT. The Act's § 3(4) expressly excludes preparations containing risk substances from §§ 19–22 and 28; an unqualified criminal possession ban for pure 4-HO-MET is not established. It is therefore restricted, not prohibited or unscheduled.

4-HO-MET is expressly named in the current binding Swiss Annex 6 Verzeichnis e schedule as a raw material/product with presumed narcotic-like effect. This is a controlled-products category: Article 7 requires EDI authorization for the listed activities and Article 20(1)(c) penalizes those activities without authorization, but these provisions do not establish an unqualified blanket possession prohibition for Verzeichnis e entries. Applicable statutory authorizations and conduct-specific exceptions must be considered.

Not specifically scheduled under the Controlled Substances Act. However, due to structural similarity to psilocin (4-HO-DMT), a Schedule I substance, it may be prosecuted under the Federal Analogue Act⁶⁶ when sold for human consumption or possessed with intent to ingest.citation needed

For the identified pure compound, 4-HO-MET is not controlled under the CDSA: Health Canada expressly places 4-HO-MET in its NPS material whose definition says NPS are not controlled under the CDSA, and the current schedules list specific tryptamines (DET, DMT, psilocin, psilocybin and etryptamine) rather than a generic tryptamine class. This does not legalize mislabeled or adulterated products, resolve other federal or provincial laws, or replace Health Canada's substance-status confirmation for a particular sample; analogue or derivative treatment remains tied to the applicable schedule heading.